Literature DB >> 17032567

New treatments for tic disorders.

Mohammad M Qasaymeh1, Jonathan W Mink.   

Abstract

Tics vary in severity from infrequent and barely noticeable to nearly continuous and highly disruptive. Treatment of tic disorders depends on the severity of the tics, the distress they cause, and the effects they have on school, work, or daily activities. Many tics do not interfere with school or everyday life and do not require specific treatment. Comorbid disorders such as attention deficit hyperactivity disorder, anxiety, and obsessive-compulsive disorder occur in more than 50% of patients. The associated comorbidity can be more bothersome than the tics themselves. Treatment should be aimed at the most troubling symptom. Education and reassurance are often sufficient for mild and occasional tics. For tics of moderate severity, clonidine and guanfacine have a reasonable safety profile. They are considered as first-line medications. With clonidine, start with 0.05 mg at bedtime. Increase as needed and as tolerated by 0.05 mg every 4 to 7 days to a maximum dosage of 0.3 to 0.4 mg/day divided three or four times a day. With guanfacine, start with 0.5 mg at bedtime. The dosage may be increased as needed and as tolerated by 0.5 mg every week to a maximum dosage of 3 to 4 mg/day, divided twice a day. There are emerging data that behavioral therapy is effective for treatment of tics in some individuals. Dopamine receptor blockers are the most potent medications for treating severe tics. The efficacy appears to be proportionate to the affinity for dopamine D2 receptors. Thus, standard antipsychotic medications such as haloperidol, pimozide, or fluphenazine are the most potent. However, these medications commonly cause bothersome side effects. Therefore, we recommend use of atypical neuroleptics before standard neuroleptics in most patients. Risperidone is usually the first choice and may have efficacy for behavior problems that often accompany tics. Start with 0.01 mg/kg/dose once a day; dosage may be increased by 0.02 mg/kg/day at weekly intervals, up to 0.06 mg/kg/dose once a day. Ziprasidone and olanzapine are reasonable alternatives.

Entities:  

Year:  2006        PMID: 17032567     DOI: 10.1007/s11940-006-0036-4

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  38 in total

Review 1.  Tourette syndrome, associated conditions and the complexities of treatment.

Authors:  M M Robertson
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  An open-label study of the treatment efficacy of olanzapine for Tourette's disorder.

Authors:  C L Budman; A Gayer; M Lesser; Q Shi; R D Bruun
Journal:  J Clin Psychiatry       Date:  2001-04       Impact factor: 4.384

3.  Diagnosing Tourette syndrome: is it a common disorder?

Authors:  Mary M Robertson
Journal:  J Psychosom Res       Date:  2003-07       Impact factor: 3.006

4.  Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome.

Authors:  Jonathan W Mink; John Walkup; Kirk A Frey; Peter Como; Danielle Cath; Mahlon R Delong; Gerald Erenberg; Joseph Jankovic; Jorge Juncos; James F Leckman; Neal Swerdlow; Veerle Visser-Vandewalle; Jerrold L Vitek
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

5.  The natural history of Tourette syndrome: a follow-up study.

Authors:  G Erenberg; R P Cruse; A D Rothner
Journal:  Ann Neurol       Date:  1987-09       Impact factor: 10.422

6.  The behavioral spectrum of tic disorders: a community-based study.

Authors:  R Kurlan; P G Como; B Miller; D Palumbo; C Deeley; E M Andresen; S Eapen; M P McDermott
Journal:  Neurology       Date:  2002-08-13       Impact factor: 9.910

7.  Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome.

Authors:  E Shapiro; A K Shapiro; G Fulop; M Hubbard; J Mandeli; J Nordlie; R A Phillips
Journal:  Arch Gen Psychiatry       Date:  1989-08

8.  Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial.

Authors:  Donald L Gilbert; J Robert Batterson; Gopalan Sethuraman; Floyd R Sallee
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2004-02       Impact factor: 8.829

9.  Course of tic severity in Tourette syndrome: the first two decades.

Authors:  J F Leckman; H Zhang; A Vitale; F Lahnin; K Lynch; C Bondi; Y S Kim; B S Peterson
Journal:  Pediatrics       Date:  1998-07       Impact factor: 7.124

10.  Deep brain stimulation in Tourette's syndrome: two targets?

Authors:  Linda Ackermans; Yasin Temel; Danielle Cath; Chris van der Linden; Richard Bruggeman; Mariska Kleijer; Pieter Nederveen; Koen Schruers; Henry Colle; Marina A J Tijssen; Veerle Visser-Vandewalle
Journal:  Mov Disord       Date:  2006-05       Impact factor: 10.338

View more
  4 in total

1.  An open-label study of guanfacine extended release for traumatic stress related symptoms in children and adolescents.

Authors:  Daniel F Connor; Damion J Grasso; Michelle D Slivinsky; Geraldine S Pearson; Alok Banga
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-05       Impact factor: 2.576

Review 2.  The role of atypical antipsychotics for treatment of Tourette's syndrome: an overview.

Authors:  Cathy L Budman
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

3.  Clonidine as a Treatment of Behavioural Disturbances in Autism Spectrum Disorder: A Systematic Literature Review.

Authors:  Krystyna Banas; Brett Sawchuk
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2020-05-01

Review 4.  Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders.

Authors:  Xue Ming; Martha Mulvey; Sharanya Mohanty; Viraj Patel
Journal:  Adolesc Health Med Ther       Date:  2011-09-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.